Future Of Pathology Research Articles

Future of pathology: who will be writing your prescriptions in the future?

Historically and in general, pathologists have been on the perimeter of disease prognosis and therapy guidance. Their role has predominantly focused on analysing a specimen and interpreting a diagnostic result, including staging of malignancies. Decisions regarding the appropriate course of therapy typically have been outside the purview of pathology. However, during the past few years, as the first step toward personalised treatments, targeted therapies with companion molecular diagnostics have experienced a significant surge in development. These diagnostic developments span the course of a disease from pre-disposition, pre-dosage and post-dosage monitoring, and include understanding the genetic characteristics of the patient and the tumour that will directly influence therapy decisions. This presentation will explore the implications of this brave new world of personalised medicine for pathologists, with focus on treatment team interaction and quality standards expectations. Historically and in general, pathologists have been on the perimeter of disease prognosis and therapy guidance. Their role has predominantly focused on analysing a specimen and interpreting a diagnostic result, including staging of malignancies. Decisions regarding the appropriate course of therapy typically have been outside the purview of pathology. However, during the past few years, as the first step toward personalised treatments, targeted therapies with companion molecular diagnostics have experienced a significant surge in development. These diagnostic developments span the course of a disease from pre-disposition, pre-dosage and post-dosage monitoring, and include understanding the genetic characteristics of the patient and the tumour that will directly influence therapy decisions. This presentation will explore the implications of this brave new world of personalised medicine for pathologists, with focus on treatment team interaction and quality standards expectations.

The Future of Pathology and Laboratory Medicine: An ASCP Task Force Report

The Future of Pathology and Laboratory Medicine: An ASCP Task Force Report

C. F. A. Culling Memorial Lecture: The Importance of Patient Selection and Its Impact on the Future of Pathology

Drug development is a highly complex and risky business. During the past 30 years, the number of new drugs approved each year has steadily declined whereas the cost of developing each new drug has grown almost exponentially. Furthermore, many drugs typically only benefit a subset of eligible patients, resulting in the need to treat many patients for the benefit of a few. This traditional “trial-anderror” practice of drug development is being progressively replaced by targeted therapies that are coupled to biomarkers which help identify patients more likely to show a treatment benefit or experience adverse events. This approach was pioneered by Genentech in the late 1990s with the codevelopment and coapproval of trastuzumab (Herceptin®) and immunohistochemical and fluorescence in situ hybridization tests devised to detect amplification and overexpression of its target, HER2. As a result, responsibility for therapeutic decision making for Herceptin® was transferred from oncologists to pathologists. Many pharmaceutical companies and academic centers are now employing biomarkers to enrich clinical trails for patients with a greater likelihood of showing a therapeutic benefit, thereby allowing trials to be conducted with fewer subjects and reducing both the time and cost of drug development. A logical extension of this concept has been captured by the term “personalized medicine,” which envisages a state when therapeutic decisions will be tailored to individuals based on their unique biomarker profile. The lure of personalized medicine has spurred the application of powerful new technologies such as microarray expression profiling, serum and tumor proteome profiling, and genomewide genetic association studies to identify biomarker signatures with the expectation that they will have greater predictive power than conventional single-analyte pathology tests such as immunohistochemistry and fluorescence in situ hybridization. It also carries the hope that the pricing structure for this new class of complex predictive tests will better reflect the true clinical value of diagnostic tests. Indeed, the diagnostic industry senses that a revolution, driven by the need to identify those patients most likely to benefit from expensive targeted therapies, has begun. This new therapeutic and diagnostic paradigm holds great promise but also creates new challenges. Using recent examples, I shall explore several issues that arose during the development of targeted therapies which highlight the need for closer collaboration between pathology laboratories and companies developing targeted therapies and companion diagnostic tests.

C. F. A. Culling Memorial Lecture: The Importance of Patient Selection and Its Impact on the Future of Pathology

C. F. A. Culling Memorial Lecture: The Importance of Patient Selection and Its Impact on the Future of Pathology

Diagnostic Electron Microscopy and Immunohistochemistry Part I: Neoplastic Diseases

Diagnostic Electron Microscopy and Immunohistochemistry Part I: Neoplastic Diseases

The future of pathology.

The future of pathology.

Pathology Manpower Needs in the Year 2000: The View From 1990

This article reviews the most important pathology manpower problems by focusing on the major segments of the manpower pipeline. Practitioners are retiring at an increasing rate. The number of newly trained pathologists available to fill vacancies is insufficient. Training program enrollments continue to decline. Trainee attrition is substantial, and significant barriers are blocking trainee recruitment efforts. The future of pathology will depend on how wisely we respond to these problems. Dr Vance is Associate Professor in the Department of Pathology at Bowman Gray School of Medicine, Winston-Salem, NC. The majority of his research has been in cytopathology, autopsy, and in manpower recruitment and retention.

The Future of Pathology

How do non-pathologists, who share our commitment to laboratory medicine as well as our workplace, perceive pathologists? Annamarie Barros has often expressed opinions that were not shared by the CAP membership. Her comments here, although many may disagree with them, provide an important perspective.

The future of pathology. Council on Long Range Planning and Development

The American Medical Association Council on Long Range Planning and Development has identified trends in the environment of medicine and has assessed their likely implications for the pathology specialty. Competition and economic pressures focused on the hospital setting are likely to continue to affect the choice of delivery site for pathology practice. During the past decade, the pathology specialty has been subject to extensive regulation, placing a new focus on the role of the laboratory within the hospital and generating new ventures for the provision of pathology services. A continuing challenge to the specialty is management innovation and adaptation in the face of regulatory restrictions and cost-containment experiments. The significant forces for change affecting the demand for services and the shape of future provision of pathology services include rapid advances in technology and scientific knowledge, funding for biomedical research, training for research pathologists, demographic trends in the population, and medical liability trends. Finally, with renewed emphasis on quality of care in the health professions, the pathology specialty has the potential to make substantial contributions to the quality and art of medical practice and is likely to remain at the center of efforts to refine methods of quality assessment and implementation.

The future of pathology

This paper reports the results of a study by and of chairmen of pathology departments in American and Canadian medical schools directed toward discovering chairmen's perceptions and attitudes about the future of pathology. Over 100 of a total of 143 chairmen participated in some or all phases of this study in which the Delphi approach was used. Sixty-five chairmen completed all four rounds of questionnaires. Most chairmen are deeply concerned about increasing federal regulation of medicine. They expect to play a greater role in all phases of medical education with more emphasis on the basic science aspects of pathology. They also foresee a desirable shifting of residency training programs away from small hospitals to the larger medical centers. This shift will result in fewer but longer training programs.

The future of pathology as visualized by the Association of Pathology Chairmen

The future of pathology as visualized by the Association of Pathology Chairmen

Pathologists: servants or colleagues?

I have a friend who in the past two years has served as a chronic consultant for pathology search committees. As a former chairman of a department of pathology, with no desire for seeking another chair (the electric chair, he called it), he is considered the proper authority on the future of pathology and on prospective candidates for a chairmanship, presumably for the same reasons for which a retired courtesan is considered an authority in matters of love. He tells me that his experience with pathology search committees has been rather depressing. In the first place, he says, surgeons and . . .

The Future of Pathology

The Future of Pathology Get access Roy R. Kracke Roy R. Kracke Note: Reprints of this address may be obtained from the Secretary’s office. Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 7, Issue 5, 1 September 1937, Pages 347–359, https://doi.org/10.1093/ajcp/7.5.347 Published: 01 September 1937 Article history Received: 21 June 1937 Published: 01 September 1937

The Past and Future of Pathology

The Past and Future of Pathology

An Address on the Future of Pathology

An Address on the Future of Pathology